Biblio Discovery — Demo Discovery Service

14 results for "David Nemirovsky"

Showing 1–14 · 0.03 seconds · RSS

  1. Journal Article

    Virtual Biostats Day: An Interactive Online Biostatistics Outreach Program Directed at High School Students in Groups Historically Underrepresented in STEM Careers

    Esther Drill; Jessica A. Lavery; Stephanie Lobaugh et al.

    Journal of Statistics and Data Science Education, Vol. 33 No. 1 · 2025 · English · DOAJ Scopus

    Persistent underrepresentation of Black and Hispanic Statistics degree holders relative to the U.S. population occurs at all levels in post-secondary education, contributing to the underrepresentation of Black and Hispanic Bio/Statisticians. Attempting to address this inequity before the…

  2. Journal Article

    Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction

    Meira Yisraeli Salman; Alexander R. Terry; Andriy Derkach et al.

    Blood Advances, Vol. 9 No. 13 · 2025 · English · DOAJ Scopus

    Abstract: The utility of a midcycle bone marrow biopsy (BMB) for early assessment of response in patients with acute myeloid leukemia (AML) after intensive chemotherapy (IC) induction is contested. Even when challenged, there is little consideration as to the possibility of different response…

  3. Journal Article

    Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

    Carlyn Rose Tan; Andriy Derkach; David Nemirovsky et al.

    Blood Cancer Journal, Vol. 13 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly…

  4. Journal Article

    Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model

    Theresia Akhlaghi; David Nemirovsky; Kylee H. Maclachlan et al.

    HemaSphere, Vol. 10 No. 9 · 2026 · English · DOAJ Scopus

    Abstract Smoldering multiple myeloma (SMM) is a heterogeneous precursor with variable risk of progression to multiple myeloma (MM). Current risk models rely on baseline features, limiting predictive accuracy. We aimed to define evolving risk factors and integrate them with the 2/20/20 model to…

  5. Journal Article

    Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

    Hamza Hashmi; Tara Sebastian; Sridevi Rajeeve et al.

    Blood Cancer Journal, Vol. 16 No. 1 · 2026 · English · DOAJ Scopus

    Abstract While CAR T has shown superior efficacy in earlier line of therapy [1, 2] for functionally high-risk multiple myeloma (FHRMM), outcomes with its use in later lines (3+) for FHR disease remain unknown. We describe a single-center experience of FHRMM patients (pts), defined as those with…

  6. Journal Article

    Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

    Benjamin Adegbite; Carlyn Rose Tan; Tala Shekarkhand et al.

    Blood Advances, Vol. 9 No. 15 · 2025 · English · DOAJ Scopus

    Abstract: Patients with relapsed/refractory (R/R) multiple myeloma (MM) are often frail with preexisting comorbidities and poor performance status (PS). To evaluate clinical characteristics and outcomes based on frailty, we conducted a single-center retrospective study of patients with R/R MM who…

  7. Journal Article

    Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

    Karthik Nath; Tala Shekarkhand; David Nemirovsky et al.

    Blood Cancer Journal, Vol. 14 No. 1 · 2024 · English · DOAJ Scopus

    Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy…

  8. Journal Article

    Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma

    Efrat Luttwak; David Nemirovsky; Sean M. Devlin et al.

    HemaSphere, Vol. 9 No. 11 · 2025 · English · DOAJ Scopus

    Abstract Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T‐cell therapy, and yet, their dose‐specific impact on outcomes remains uncertain. We retrospectively…

  9. Journal Article

    Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL

    Daniela R. Anderson; Radhika Gangaraju; Wafik George Sedhom et al.

    Blood Advances, Vol. 10 No. 3 · 2026 · English · DOAJ Scopus

    Abstract: The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) receiving asparaginase-based induction is high despite primary thromboprophylaxis. Our aim was to derive and externally validate a VTE risk prediction model in patients with ALL receiving…